文章摘要

钠 - 葡萄糖共转运蛋白 2 抑制剂治疗 2 型糖尿病合并 非酒精性脂肪肝的研究进展

作者: 1秦玉, 1肖新华
1 南华大学附属第一医院内分泌科，湖南 衡阳 421001
通讯: 肖新华 Email: xiaoxinhua139@163.com

摘要

随着全球范围内肥胖和2型糖尿病(type 2 diabetes mellitus，T2DM)发病率的急剧增长，约70%的 肥胖糖尿病患者同时合并有非酒精性脂肪肝(non-alcoholic fatty liver disease，NAFLD)，甚至多达 30%~40%的患者合并有非酒精性脂肪性肝炎(non-alcoholic steatohepatitis，NASH)。目前T2DM合 并NAFLD已成为全球关注的健康问题之一。尽管如此，近年来大量相关研究表明钠-葡萄糖共转运 蛋白2(sodium-glucose co-transporter 2，SGLT2)抑制剂显著降糖的同时，肝相关不良事件的发生明 显减少，为NAFLD的治疗提供了新思路。
关键词： 钠-葡萄糖共转运蛋白2抑制剂 肥胖 2型糖尿病 非酒精性脂肪肝

Research progress of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes mellitus with non-alcoholic fatty liver

Authors: 1Qin Yu, 1Xiao Xinhua
1 Department of Endocrinology, First A liated Hospital of University of South China, Hengyang Hunan 421001, China

CorrespondingAuthor: Xiao Xinhua Email: xiaoxinhua139@163.com

Abstract

With the incidence of obesity and type 2 diabetes mellitus (T2DM) increasing dramatically worldwide, about 70% of obese diabetics combined with non-alcoholic fa y liver disease (NAFLD) and even as many as 30%–40% combined with non-alcoholic steatohepatitis (NASH). At present, T2DM with NAFLD has become one of the global health concerns. Even so, in recent years, a great deal of researches on sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown that they have remarkable e ect of lowering blood sugar, also, the incidence of adverse events related to liver has signi cantly reduced, thus providing new ideas for the treatment of NAFLD.
Keywords： sodium-glucose co-transporter 2 inhibitor obesity type 2 diabetes mellitus nonalcoholic fa y liver disease

文章选项

下载引文

分享